ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Geert R. D'Haens  1     Marla C. Dubinsky  2     Laurent Peyrin-Biroulet  3, 4     Silvio Danese  5     Bruce E. Sands  5     Doug Wolf  6     Andres Yarur  7     Michael Chiorean  8     Danielle Dray  9     Irene Modesto  10     Huaming Tan  11     Guibao Gu  12     Claudia Lopez  13     Chinyu Su  14     Jinkun Zhang  15     Fabio Cataldi  15     Aoibhinn McDonnell  16     Stefan Schreiber  17     Brian G. Feagan  18, 19     Severine Vermeire  20    
1 Amsterdam University Medical Centres, Amsterdam, Netherlands
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 University of Lorraine, CHRU-Nancy, Nancy, France
4 University of Lorraine, Inserm, NGERE, Nancy, France
5 IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
6 Atlanta Gastroenterology Associates, Atlanta, United States
7 Cedars-Sinai Medical Center, Los Angeles, United States
8 Swedish Medical Center, Seattle, United States
9 Pfizer Inc, New York, United States
10 Pfizer Inc, Madrid, Spain
11 Pfizer Inc, Groton, United States
12 Pfizer Inc, San Diego, United States
13 Landos Biopharma, Blacksburg, United States
14 Pfizer Inc, Collegeville, United States
15 Arena Pharmaceuticals, San Diego, United States
16 Pfizer Ltd, Sandwich, United Kingdom
17 University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
18 Western University, London, Canada
19 Alimentiv Inc, London, Canada
20 University Hospital Leuven, Leuven, Belgium

Topic
IBD

Conference
UEG Week Copenhagen 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing